Mumbai, February 27, 2018: The drug firm, USV Private Ltd. said today that the US Food and Drug Administration (USFDA) lifted its warning letter issued in March 2017 to the Daman facility, following corrective actions taken by the company. USV Daman manufactures aseptic and oral solid dosage products for the US market.
Mr. Prashant Tewari, Managing Director, USV Pvt. Ltd. said, “We are extremely pleased with this outcome. Our team worked closely to address the US FDA concerns. We will continue to strengthen our quality system through continuous improvement programs. We expect 7 ANDA approvals in the near future and are expecting a 40-50% growth in our US business over the next 2 years.”
Earlier in November 2017 the USV Lote site, that supplies Active Pharmaceutical Ingredients (API) to US Market, received an audit close from US FDA.
Corporate Comm India(CCI Newswire)
Patients Embrace Flexibility with 37% of Online Doctor Consultations now happening even After 6 PM,…
Launches Advanced Pathology Laboratory Offering Over 2500+ Tests in collaboration with Parashar Pathology Clinic in…
By Dr. Brajmohan Singh, Cardiothoracic and Vascular Surgeon, HCG Hospitals, Bhavnagar Cardiovascular health is vital…
By Ms. Soumita Biswas, Chief Clinical Nutritionist, Aster RV Hospital Every year, International Mind-Body Wellness…
By Dr Bhavisha Ghughare, Consultant –Surgical Oncology and Breast Oncoplastic Surgeon, HCG Cancer Center, Borivali,…
By Dr. Srinivasa Murthy C L, Lead Paediatrics, Consultant – Paediatrics and Neonatology, Aster Women…